WEKO3
アイテム
C-11 METHIONINE POSITRON EMISSION TOMOGRAPHY AND SURVIVAL IN PATIENTS WITH NASAL MALIGNANT MELANOMA TREATED BY CARBON ION RADIOTHERAPY.
https://repo.qst.go.jp/records/68005
https://repo.qst.go.jp/records/68005a308b00c-d383-4fe4-9556-a1ab445ea708
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2005-01-28 | |||||
| タイトル | ||||||
| タイトル | C-11 METHIONINE POSITRON EMISSION TOMOGRAPHY AND SURVIVAL IN PATIENTS WITH NASAL MALIGNANT MELANOMA TREATED BY CARBON ION RADIOTHERAPY. | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Ishikawa, Hiroyuki
× Ishikawa, Hiroyuki× Yoshikawa, Kyosan× Sagou, Kenji× Tamura, Katsumi× Koga, Masahisa× Kandatsu, Susumu× Mizoe, Junetsu× Tanada, Shuji× Tsujii, Hirohiko× et.al× 石川 博之× 吉川 京燦× 佐合 賢治× 田村 克巳× 古賀 雅久× 神立 進× 溝江 純悦× 棚田 修二× 辻井 博彦 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Objectives:Malignant melanoma in head and neck region accounts for 30 to 56 percent of all malignant melanoma in Japan,and nasal malignant melanoma is especially very rare among them. The carbon ion radiotherapy (CIRT) has been introduced in our institute,and we have treated the nasal malignant melanoma using carbon ion beam. We evaluated whether C-11 methionine (MET) uptake and its change after CIRT were the early survival factors in patients with nasal malignant melanoma. Methods:MET-PET was prospectively performed in 28 patients with nasal malignant melanoma before CIRT, and 25 patients among them were also received MET-PET after CIRT. Patients were followed for 4.8 to 35.3 months (mean:16.2 months) after CIRT. Tumor MET uptake was measured with the semiquantitative tumor-to-muscle ratio (TMR).The MET uptake in the tumor and the result of short-term prognosis were entered into Kaplan-Meier analysis. The relationship between the change of MET uptake after CIRT and the result of local control rate, CR (complete remission) or PR (partial response) group and SD (stable disease) group, was also analyzed. Results:The overall median survival time was 12.9 months. Patients with a baseline TMR of < 10.7 had a significant better survival than patients with a baseline TMR > 10.7 (2-year survival rate:68.8% versus 31.2%, P=0.038). Patients with a post CIRT TMR < 7.0 had a better survival than that with a post CIRT TMR > 7.0(2-year survival rate:79.0% versus 21.0%, P=0.043). No statistically significant difference of survival rate was observed between any two patient groups of posttherapeutic MET uptake change. A significant higher local control rate was observed in patients with posttherapeutic MET uptake change of > 30% than patients in lower change group (2-yaer local control rate:72.5% versus 27.5%, P=0.018). Conclusions:MET uptake, as measured by either baseline or post CIRT TMR was an independent predictor of survival in patients with nasal malignant melanoma treated by carbon ion radiotherapy, while posttherapeutic MET uptake change might have potential value for predicting local control. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Society of nuclear medicine's 51st. annual meeting | |||||
| 発表年月日 | ||||||
| 日付 | 2004-06-25 | |||||
| 日付タイプ | Issued | |||||
